Fri, 22nd Nov 2013 13:47
LONDON, Nov 22 (Reuters) - European regulators said onFriday they had recommended approval of a new drug for HIV fromGlaxoSmithKline and a novel hepatitis C treatment fromGilead Sciences.
The European Medicine Agency (EMA) also gave a green lightto an Otsuka tuberculosis drug, following a review ofan earlier rejection.
Recommendations for marketing approval by the EMA'sCommittee for Medicinal Products for Human Use (CHMP) arenormally endorsed by the European Commission within a couple ofmonths.
PARIS, May 12 (Reuters) - U.S. internet giant Amazon will announce a new 1.2 billion euros ($1.3 billion) investment in France, the French presidenc...
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:
May 2 (Reuters) - U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a...
Glaxosmithkline (GSK)